Acacia Research (ACTG) Returns to Profitability With $0.03 EPS in Q4 2025 on Flat $50.1M Revenue
Acacia Research swings to $0.03 adjusted EPS in Q4 2025, matching prior quarter and reversing year-ago loss, as revenue holds…
ADVERTISEMENT
Company News
BridgeBio (BBIO) Reports Wider Q4 Loss of $1/Share vs $0.63 Estimate; Stock Surges 13%
BridgeBio posts wider-than-expected Q4 loss of $0.94/share on $154.2M revenue; stock surges 13% despite 50.6% earnings miss.
DNTH Stock Jumps 21.5% Despite Wider-Than-Expected Q4 Loss as Pipeline Prospects Fuel Rally
Dianthus Therapeutics posts wider-than-expected Q4 loss of $1.43/share on collapsing revenue, yet shares surge 21.5% on pipeline optimism.
Bloom Energy (BE) Surges 12% Despite Adjusted Loss of $0.30 Per Share, Weak Q1 Outlook
Bloom Energy posts GAAP EPS beat at $0.45 vs $0.30 estimate, but adjusted EPS of -$0.30 and weak Q1 guidance…
DENTSPLY SIRONA (XRAY) Insider Gregory T. Lucier Buys 15,000 Shares at $12.45, Boosting Stake 30%
Gregory T. Lucier purchased 15,000 shares at $12.445, deploying $186,675 to increase his stake by 30% to 65,000 shares.
URBN Insiders Surrender Over 30K Shares Valued at $2M for Tax Obligations as Stock Trades at $65.62
URBN executives forfeited 30,862 shares worth $2.03M for tax withholding on March 9, led by Global CEO Sheila Harrington's 3,959-share…
SCI President Forfeits 3,300 Shares at $81.42 in Tax Withholding Transaction
SCI President forfeited 3,300 shares at $81.42 for tax obligations, part of a four-executive cluster totaling $675,053 in routine equity…
TTMI Shares Surge 10.1% After Beating Q4 Earnings Estimates for Fourth Consecutive Quarter
TTMI posts Q4 EPS of $0.70 vs $0.68 estimate, revenue reaches $774.3M as shares jump 10.1% on fourth straight earnings…
Legend Biotech (LEGN) Turns Profitable With $0.01 EPS on 64% Revenue Surge to $306.3M in Q4
Legend Biotech posts $0.01 adjusted EPS in Q4 2025, turning profitable on 64% revenue growth to $306.3M as commercial momentum…
Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year
Cullinan Therapeutics posts $0.73 per share loss in Q4 2025, matching year-ago results as the pre-revenue biotech maintains clinical development…